CStone Pharmaceuticals

CStone Pharmaceuticals is a biopharmaceutical company that researches and develops anti-cancer therapies for cancer patients in Mainland China and internationally. Its products include CEJEMLY (sugemalimab), a monoclonal antibody against PD ligand 1 for non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor approved by China NMPA for adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. The company has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. Incorporated in 2015, CStone Pharmaceuticals is headquartered in Suzhou, China.